Hitesh portfolio

Hi @hitesh2710,

Wondering why omkar is just a opportunistic bet, but not a core or emerging portfolio pick ? You know everything about this company. Just putting down my understanding here … I see IP led growth in this company and they are continuously coming up with novel process (which they eventually patent it) to cut production cost of intermediates and get new orders from pharma companies. They are progressing good in Vet API segment as well. Only drag could be their commodity iodine business. CRISIL is continuously monitoring this company and the latest fair value of Omkr given by them is 220+. Given the expansion is also kicking in and aggressive play by technically sound father & son, shouldn’t we bet on this for next 3 years at least ? Of course, with regular quarterly results monitoring.